MUTUAL TERMINATION AND RELEASE AGREEMENT

This Mutual Termination and Release Agreement (this “Agreement”) is entered into by China SXT Pharmaceuticals, Inc., a British Virgin Islands company (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and, together with the Company, the “Parties”), in respect of the Securities Purchase Agreement dated October 7, 2026 between the Company and the Purchasers (the “SPA”). The Parties confirm that the closing under the SPA has not occurred, no purchase price has been paid, and no shares or warrants have been issued or delivered under the SPA.

In consideration of the mutual agreements and releases below, the Parties agree as follows:

…

---

Exhibit 10.2

Execution Version

JAMES C. CLEMMER

CONSULTING AGREEMENT

THIS CONSULTING AGREEMENT (the “Agreement”) is entered into effective as of November 2, 2026 (the “Effective Date”), by and between AngioDynamics, Inc., a Delaware corporation (the “Company”), on the one hand, and James C. Clemmer, an individual (the “Consultant”), on the other hand.

WHEREAS, Consultant currently serves as the President and Chief Executive Officer of the Company;

WHEREAS, Consultant and the Company entered into that certain Transition and Retirement Agreement (the “Transition Agreement”), dated as of January 2, 2026, pursuant to which, on the earlier of (i) the appointment of a successor in the role of Chief Executive Officer of the Company and (ii) November 30, 2026, Consultant shall retire as President and Chief Executive Officer of the Company and its subsidiaries and shall transition to the role of consultant to the Company;

WHEREAS, the Company appointed a new President and Chief Executive Officer effective as of November 2, 2026; and

…

---

Exhibit 10.1

Execution Version

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is entered into by and between AngioDynamics, Inc, a Delaware corporation (the “Company”) and Eric Honroth (“Executive”) (together, the “Parties” and individually, a “Party”).

WHEREAS, Executive wishes to be employed by the Company, and the Company wishes to secure the employment of Executive, under the terms and conditions described below.

NOW THEREFORE, in consideration of the foregoing and in consideration of the mutual promises and agreements contained herein, the Parties hereto agree as follows:

1.           Position; Location.

…

---

Exhibit 10.3

Form of AngioDynamics Retention and Severance Letter Agreement

October 5, 2026

Personal and Confidential

[Employee Name]

[Address]

Re:	AngioDynamics Retention Incentive Opportunity

Dear [Name]:

Given your critical role, skills and knowledge, your efforts on behalf of AngioDynamics are particularly important at this time. Therefore, on behalf of the AngioDynamics Board of Directors, the Company is offering you a retention incentive and severance benefit beyond your regular compensation to recognize your continued commitment to providing critical leadership to the Company during this period of transition.

Specifically, AngioDynamics is offering you the opportunity to receive additional severance benefits as a result of your continued retention as an employee through the transition to a new Chief Executive Officer as set forth below:

…

IAMBIC THERAPEUTICS, INC.

OUTSIDE DIRECTOR COMPENSATION POLICY

Iambic Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees or officers of the Company (“Outside Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2026 Equity Incentive Plan, as amended from time to time, or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or similar term in the equity plan then in place under which the equity award is granted (the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a

…

IAMBIC THERAPEUTICS, INC.

2026 EMPLOYEE STOCK PURCHASE PLAN

1.

Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Code Section 423(the “423 Component”) and a component that is not intended to qualify as an “employee stock purchase plan” under Code Section 423(the “Non‑423 Component”). The provisions of the 423Component, accordingly, will be construed so as to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Code Section 423. In addition, this Plan authorizes the grant of Purchase Rights under the Non‑423 Component that does not qualify as an “employee stock purchase plan” under Code Section 423. Except as otherwise provided in the Plan or determined by the Administrator, the Non-423 Component will operate and be administered in the same manner as the 4

…

IAMBIC THERAPEUTICS, INC.

2026 EQUITY INCENTIVE PLAN

1. Purposes of the Plan; Award Types.

(a) Purposes of the Plan. The purposes of this Plan areto attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business.

(b) Award Types. The Plan permits the grant of Incentive Stock Options to any ISO Employee and the grant of Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Awards, and Other Stock Awards to any Service Provider.

2. Definitions. The following definitions are used in this Plan:

(a) “Administrator” means Administrator as defined in Section 4(a).

…

Execution Version

FIRST AMENDMENT TO CREDIT AGREEMENT

This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of October 2, 2026 (the “First Amendment Effective Date”), is by and among TETRA TECHNOLOGIES, INC., a Delaware corporation (the “Borrower”), the other Loan Parties party hereto, the Lenders party hereto, and SILVER POINT FINANCE, LLC, as Administrative Agent (in such capacity, the “Administrative Agent”).

WITNESSETH:

WHEREAS, the Borrower entered into that certain Credit Agreement dated as of January 12, 2024, by and among the Borrower, the other Loan Parties party thereto, Silver Point Finance, LLC, as the administrative agent thereunder and the Lenders party thereto (as amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof, the “Existing Credit Agreement”, and the Existing Credit Agreement, as amended by this Amendment, the “Credit Agreement”; capitalized terms used in this Amendment, to the extent not otherwise defined herein, shall have the same meanings as in the Credit Agreement);

…

**RESTRICTIVE COVENANT, CONFIDENTIALITY AND INVENTIONS AGREEMENT **

This Restrictive Covenant, Confidentiality and Inventions Agreement (“Agreement”) is made and entered into effective as October 12, 2026, by and between Henry Schein, Inc., a Delaware corporation headquartered in New York (the “Company”) and Emmanuel Caprais (“Employee”).

***RECITALS ***

WHEREAS, Employee is being offered employment by the Company in the key role of Senior Financial Advisor, transitioning to Senior Vice President, Chief Financial Officer, and the projected responsibilities of this role include, among others, providing strategic and financial leadership for the Company, overseeing the Company’s global finance organization and financial strategy, planning, reporting, controls and capital allocation, partnering with senior leadership to drive financial performance and long-term value creation, and supporting the Company’s strategic priorities and overall business objectives; and

…

October 6, 2026

Emmanuel Caprais

Dear Emmanuel:

On behalf of Henry Schein, Inc. (the “Company”), this letter will serve to confirm our offer to you. Your anticipated start date will be October 12, 2026. You will initially serve in the position of Senior Financial Advisor. Effective November 4, 2026 (the “Transition Date”), you will transition to the position of Senior Vice President, Chief Financial Officer. You will report to Frederick Lowery, Chief Executive Officer (or his successor), in both positions. Both of these positions will be based out of Melville, New York. Please respond to this offer within three business days.

Below I have outlined the compensation and benefit components of our offer:

…

**SECURITIES PURCHASE AGREEMENT **

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).

WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act;

…

**REGISTRATION RIGHTS AGREEMENT **

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 7, 2026, is entered into by and among Atrium Therapeutics, Inc.,** **a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

**WHEREAS: **

…